| Entry |
|
|---|
| Name |
Lofexidine (INN) |
|---|
| Formula |
C11H12Cl2N2O
|
|---|
| Exact mass |
258.0327
|
|---|
| Mol weight |
259.1318
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Cardiovascular agent
DG01456 Adrenergic receptor agonist
DG01450 alpha-Adrenergic receptor agonist
DG01449 alpha2-Adrenergic receptor agonist
|
|---|
| Remark |
| Product (DG01001): | D04765<US> |
|
|---|
| Efficacy |
Antihypertensive, Vasodilator, alpha2-Adrenergic receptor agonist |
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N07 OTHER NERVOUS SYSTEM DRUGS
N07B DRUGS USED IN ADDICTIVE DISORDERS
N07BC Drugs used in opioid dependence
N07BC04 Lofexidine
D08141 Lofexidine (INN)
Drug groups [BR:br08330]
Cardiovascular agent
DG01456 Adrenergic receptor agonist
DG01450 alpha-Adrenergic receptor agonist
DG01449 alpha2-Adrenergic receptor agonist
DG01001 Lofexidine
D08141 Lofexidine
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Adrenaline
ADRA2
D08141 Lofexidine (INN)
Drug groups [BR:br08330]
Cardiovascular agent
DG01456 Adrenergic receptor agonist
DG01450 alpha-Adrenergic receptor agonist
DG01449 alpha2-Adrenergic receptor agonist
DG01001 Lofexidine
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 16
1 C8x C 20.0900 -18.1300
2 C8x C 20.0900 -19.5300
3 C8x C 21.3500 -20.2300
4 C8y C 22.5400 -19.5300
5 C8y C 22.5400 -18.1300
6 C8y C 21.3500 -17.4300
7 X Cl 21.3500 -16.0300
8 X Cl 23.8000 -20.2300
9 O2a O 23.8000 -17.4300
10 C1c C 24.9900 -18.1300
11 C2y C 26.1800 -17.4300
12 C1a C 24.9900 -19.5300
13 N1x N 27.5100 -17.8500
14 C1x C 28.2800 -16.7300
15 C1x C 27.5100 -15.6100
16 N2x N 26.1800 -16.0300
BOND 17
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 6 7 1
8 4 8 1
9 5 9 1
10 9 10 1
11 10 11 1
12 10 12 1
13 11 13 1
14 13 14 1
15 14 15 1
16 15 16 1
17 11 16 2
|
|---|
